Cardiovascular diseases have been rising at an alarming rate due to various reasons. The changing lifestyles of the population, stressed minds, inconsistent eating habits and the consumption of junk food, and the rise in smoking and alcohol consumption have all contributed towards the rise in cardiovascular diseases. The need for valve replacement therapy is one such cardiovascular treatment gaining a lot of traction lately. The global transcatheter heart valve replacement and repair (THVR) market valued US$1.61 bn in 2015 and is projected to rise at a strong 13.9% CAGR for the forecast period of 2016 up to 2026.
Product Defects, Recalls Restraining Global THVR Market
The risks associated with open-heart surgeries is high resulting in major fatalities in case of a mishap during the surgery. On the other hand valve replacement surgeries provide a better chance as the surgery is less intrusive and the recovery time for the patient is on the shorter side. Moreover the rise in aortic stenosis disorder and mitral regurgitation has resulted in the rise in demand for valve replacement therapies, which is driving the global THVR market.
The treatment being less intrusive and employing the latest in medical technology is capital intensive. Majority population are unable to opt for the treatment owing to unavailability of funds. The lack of reimbursements from the insurance companies in this regard is hampering the global market a great deal. As the technology is new, the clinical trials conducted are limited resulting in the presence of certain risks in case of the surgery. Manufacturers are constantly developing the product. The result is the rise in recalls due to product defects is expected to restrain the global transcatheter heart valve replacement and repair market.
Looking for Details Report TOC: http://www.persistencemarketresearch.com/market-research/transcatheter-heart-valve-replacement-repair-market/toc
Major Companies Acquiring Competitors to Increase Share, Gain Technology
The global THVR market is witnessing major growth in demand. The technology has developed manifold to include new designs and surgery techniques. Major players in the market are actively acquiring the small startups who have developed the new designs to incorporate the product under their banners and increase sales. In 2015, companies such as Edwards Lifesciences acquired CardiAQ Valve Technologies to gain the mitral valve regurgitation therapy developed by CardiAQ as the device is touted to be the best-in-class design in the global market.
Other acquisitions include Abbott buying Tendyne for the same mitral regurgitation treatment. It also invested into Cephea Valve Technologies with the option open for a buyout in the future mentioned in the agreement. The reason provided for the acquisition and merger with the two companies respectively is owing to the difference in treatment approach such as the transapical approach followed by Tendyne as compared to the transfemoral approach followed by Cephea Valve Technologies. Medtronic Inc. is also an active company in the acquisitions scene with the buyout of CoreValve.
Interested to know more? Follow the link: http://www.persistencemarketresearch.com/samples/11167
Key players in the global transcatheter heart valve replacement and repair market include JenaValve Technology, Braile Biomedica, Boston Scientific Corporation, Medtronic, Inc., Symetis, Abbott Laboratories, St. Jude Medical, Inc., and Edwards LifeSciences Corporation.